Education
About Us
Working with TipRanks
Follow Us
Bioceres Crop Solutions (BIOX)
NASDAQ:BIOX
Top Page
Bioceres Crop Solutions
(NASDAQ:BIOX)
Rating:67Neutral
Price Target:
$5.50
▲(10.22%Upside)
Positive Factors
Cost Management
Management's focus on long-term seed trait development and biologicals is expected to save approximately $5M annually, benefiting cash flow and reducing operating expenses.
International Growth
Bioceres’ internal initiatives have expanded the international growth opportunity of its core businesses, with expectations for a significant contribution from their distribution agreement with Syngenta.
Market Expansion
The EPA approved Bioceres’ registration of Rinotec, expanding the technology into the US market, enhancing their position in the alternative pesticides market in the US and Brazil.
Negative Factors
Financial Performance
Bioceres Crop Solutions reported revenues of $60.6M, down 28% year-over-year, and an adjusted EBITDA of $9M, down approximately 57% year-over-year.
Geographical Challenges
Sales across each business segment declined, with Crop Protection down ~23% due to reduced demand in Argentina.
Market Outlook
Shares fell 14%, which we attribute to an ambiguous 2H’25 outlook.
Bioceres Crop Solutions (BIOX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$287.84M
Dividend YieldN/A
Average Volume (3M)133.22K
Price to Earnings (P/E)193.5
Beta (1Y)0.57
Revenue Growth-13.98%
EPS Growth-403.56%
CountryUS
Employees400
SectorBasic Materials
Sector Strength69
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.02
Shares Outstanding62,710,846
10 Day Avg. Volume141,299
30 Day Avg. Volume133,221
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio13.21
Enterprise Value/Market Cap1.79
Enterprise Value/Revenue0.30
Enterprise Value/Gross Profit3.39
Enterprise Value/Ebitda2.93
Forecast
1Y Price Target
$7.17Price Target Upside43.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bioceres Crop Solutions Business Overview & Revenue Model
Company DescriptionBioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program. It operates in Argentina, Uruguay, France, South Africa, and internationally. The company was founded in 2001 and is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.
How the Company Makes MoneyBioceres Crop Solutions makes money through the sale of its agricultural biotechnology products, which include genetically modified seeds engineered for higher yields and resistance to environmental stresses. Additionally, the company generates revenue from biological inoculants that improve soil health and crop productivity, and from micro-beaded fertilizers that offer efficient nutrient delivery. Key revenue streams include direct sales to farmers and agricultural distributors. The company also benefits from strategic partnerships and collaborations with other agricultural firms and research institutions, which help in the development and distribution of its products.
Bioceres Crop Solutions Earnings Call Summary
Earnings Call Date:May 21, 2025
(Q3-2025)
| % Change Since: 7.31%|
Next Earnings Date:Sep 11, 2025
Earnings Call Sentiment Neutral
Bioceres Crop Solutions experienced significant challenges this quarter, primarily due to the absence of the prior year's Syngenta payments and a slow market in Argentina. However, the company achieved exceptional cash flow performance and received important regulatory approvals for Rinotec, positioning it for future growth. The highlights and lowlights are fairly balanced this quarter.Q3-2025 Updates
Positive Updates
Exceptional Cash Flow Performance
Bioceres reported a $40 million improvement in cash flow year-over-year, helping reduce debt and improve cash position.
Approval of Rinotec
Long-awaited EPA approval of Rinotec, allowing Bioceres to offer a full suite of biological solutions for pest control and plant health globally.
Growth in Seed and Integrated Products
Revenues in seed and integrated products increased by 26%, primarily fueled by accelerated sales of HB4 grain.
Successful Cash Management
Net cash from operating activities reached $23.3 million, a $40.7 million improvement compared to the previous year.
Positive Developments in U.S. and Mexico
U.S. and Mexico markets showed good growth, with early signs of recovery and stabilization in certain areas.
Negative Updates
Revenue Decline
Total revenues fell to $60.6 million from $84 million the previous year, largely due to the absence of a $16 million accrual from Syngenta's initial down payment.
Gross Profit Decrease
Gross profit dropped to $24 million from $42.6 million last year, primarily affected by the absence of the Syngenta payment.
Challenges in Argentina
Argentina experienced a slow third quarter with reduced commercial activity and seasonality impacting revenues.
Adjusted EBITDA Decline
Adjusted EBITDA fell to $9 million from $21.1 million last year, impacted by the absence of the Syngenta on-payment accrual.
Company Guidance
In the Bioceres Crop Solutions Fiscal Third Quarter 2025 earnings call, several key metrics and achievements were highlighted. Notably, the company reported a $40 million year-over-year improvement in cash flow, which played a significant role in reducing debt and enhancing the cash position. Despite a drop in total revenues to $60.6 million from $84 million the previous year, primarily due to the absence of a $16 million accrual from a Syngenta collaboration, the company maintained a consistent gross margin close to historical levels. The adjusted EBITDA for the quarter was $9 million, down from $21.1 million the previous year, but efforts to streamline the seed business and overall cost structure are expected to yield future savings. The company's strategic focus on enhancing cash generation and capital allocation has been evident, with a notable $23.3 million net cash from operating activities reported, marking a $40.7 million improvement from the previous year. Looking ahead, the launch of Rinotec and further penetration into conventional acreage markets are anticipated to drive future growth.Bioceres Crop Solutions Financial Statement Overview
Summary
Bioceres Crop Solutions demonstrates solid cash flow management and a strong equity base. However, profitability and revenue stability are concerns, with high debt levels and inconsistent profitability metrics indicating potential financial risk.Income Statement
Bioceres Crop Solutions shows volatile revenue trends with significant fluctuations in net income, indicating instability. The company has recently experienced a negative net profit margin and declining EBIT margins in TTM. Despite past growth, the current revenue trajectory suggests a need for consistency in profitability.65
Positive
Balance Sheet
The company's balance sheet shows moderate leverage with a debt-to-equity ratio that has increased over time, indicating rising financial risk. However, the equity ratio remains healthy, reflecting a strong equity position. The ROE has been inconsistent, highlighting the need for improved profitability.70
Positive
Cash Flow
The cash flow analysis indicates robust operating cash flow relative to net income in TTM, suggesting effective cash management. However, fluctuations in free cash flow growth and historical negative free cash flows point to potential liquidity concerns. The company needs to stabilize free cash flow generation.75
Positive
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 383.31M | 464.83M | 419.45M | 328.46M | 206.70M | 172.35M |
| Gross Profit | 152.46M | 181.59M | 180.25M | 126.44M | 90.88M | 79.49M |
| EBITDA | 34.28M | 55.45M | 61.09M | 40.03M | 37.04M | 29.58M |
| Net Income | -8.23M | 3.24M | 18.78M | -7.20M | -6.87M | 3.36M |
Balance Sheet | ||||||
| Total Assets | 798.21M | 850.63M | 818.06M | 518.22M | 394.59M | 297.56M |
| Cash, Cash Equivalents and Short-Term Investments | 39.35M | 56.17M | 60.05M | 38.61M | 46.78M | 51.57M |
| Total Debt | 273.30M | 270.95M | 257.41M | 169.79M | 174.58M | 149.09M |
| Total Liabilities | 453.24M | 501.06M | 487.56M | 359.92M | 304.30M | 236.81M |
| Stockholders Equity | 308.71M | 314.01M | 298.85M | 127.61M | 67.74M | 46.18M |
Cash Flow | ||||||
| Free Cash Flow | 21.32M | 18.93M | -19.97M | -26.51M | -20.13M | 4.82M |
| Operating Cash Flow | 36.36M | 41.72M | 2.59M | -17.52M | -6.21M | 9.32M |
| Investing Cash Flow | -7.91M | -28.73M | -25.73M | 2.90M | -8.31M | -7.80M |
| Financing Cash Flow | -19.67M | -10.06M | 32.95M | 14.82M | 7.36M | 33.53M |
Bioceres Crop Solutions Technical Analysis
Positive
4.99
Price Trends
4.60
Positive
4.57
Positive
5.77
Negative
Market Momentum
<0.01
Negative
58.05
Neutral
64.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOX, the sentiment is Positive. The current price of 4.99 is above the 20-day moving average (MA) of 4.69, above the 50-day MA of 4.60, and below the 200-day MA of 5.77, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.05 is Neutral, neither overbought nor oversold. The STOCH value of 64.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIOX.
Bioceres Crop Solutions Risk Analysis
Bioceres Crop Solutions disclosed 68 risk factors in its most recent earnings report. Bioceres Crop Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Certain of the Rizobacter shares we own are subject to a judicial injunction that, if decided unfavorably to us, would require us to surrender part of our interest in Rizobacter thereby reducing our equity interest in Rizobacter. Q2, 2024
2.
The disposition or sale of our ordinary shares may be subject to taxation in Argentina. Q2, 2024
3.
Our share repurchase program may reduce liquidity. Q2, 2024
Bioceres Crop Solutions Peers Comparison
Overall Rating
UnderperformOutperform
Sector (43)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $287.84M | 193.48 | -3.00% | ― | -13.98% | -403.56% | |
60 Neutral | $480.87M | ― | -35.32% | ― | 0.63% | -369.50% | |
57 Neutral | $3.87B | 133.99 | 4.98% | 3.83% | 0.75% | ― | |
50 Neutral | $6.06M | ― | -7.89% | ― | -2.81% | 72.03% | |
48 Neutral | $238.65M | ― | -69.68% | ― | ― | ― | |
43 Neutral | AU$1.37B | -6.17 | -40.62% | 4.19% | -4.78% | -42.91% | |
43 Neutral | $138.66M | ― | -45.53% | 3.01% | -10.46% | -2007.33% |
* Basic Materials Sector Average
Performance Comparison
BIOX
Bioceres Crop Solutions
4.99
-6.21
-55.45%
AVD
American Vanguard
4.03
-4.24
-51.27%
IPI
Intrepid Potash
36.62
13.63
59.29%
SMG
Scotts Miracle-Gro Company
68.97
8.69
14.42%
RKDA
Arcadia Biosciences
4.63
1.61
53.31%
LVRO
Lavoro Limited
2.04
-3.19
-60.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.